Menlo Therapeutics Inc. (MNLO) News
Filter MNLO News Items
MNLO News Results
|Event/Time||Symbol||Company||News Detail||Start||End||Change||POWR Rating|
|Loading, please wait...|
Latest MNLO News From Around the Web
Below are the latest news stories about Menlo Therapeutics Inc that investors may wish to consider to help them evaluate MNLO as an investment opportunity.
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
Menlo Therapeutics: Strong Amzeeq Launch, Recent Zilxi Approval And Positive FCD105 Results Point To Growth Ahead
Since January of this year, shares of Menlo Therapeutics (MNLO) (formerly Foamix) have been cut by roughly two-thirds, given the fallout of the Coronavirus pandemic, as well as the lackluster result of the merger between Foamix and Menlo to form the newly combined company. With the failure of serlopitant, the...
Menlo Therapeutics (MNLO) has priced its public offering of ~27.1M common shares at $1.85/share, for expected gross proceeds of $50,042,500.Underwriters' over-allotment is an additional 4,057,500 shares.Closing date is June 9.Shares are down 17% premarket....
The decline came after the company announced the pricing of a stock offering Friday morning. The number of shares being offered represents nearly 20% of the total number of outstanding shares. Stocks usually fall on public offerings because the value of existing shares is diluted.
Menlo Therapeutics Inc. (“Menlo”) (MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced the pricing of an underwritten public offering of 27,050,000 shares of common stock at a price to the public of $1.85 per share. All of the shares of common stock to be sold in the offering will be offered by Menlo. In addition, Menlo has granted the underwriters a 30-day option to purchase up to an additional 4,057,500 shares of its common stock.
Menlo Therapeutics Inc. (“Menlo”) (MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the common stock to be sold in the offering will be offered by Menlo. In addition, Menlo expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.
The following slide deck was published by Menlo Therapeutics Inc. in conjunction with this event....
2020 has been kind to small-cap biotechs. Some have spiked upwards dramatically this year, mostly on the hope of finding solutions to COVID-19, be it a treatment or vaccine. Those who haven’t gotten in on the action yet still yearn to join the fray, might justifiably feel a sense of apprehension. An investment in a stock that has already posted double, or in some cases, triple digit gains feels like risky business.However, the volatile biotech world always presents fresh opportunities. Northland Securities analyst Tim Chiang argues the case for dermatology-focused Menlo Therapeutics (MNLO). Shares are down by a depressing 49% so far this year, but Chiang is anticipating hefty returns from the small-cap.Based on what, you ask?Last Friday, the FDA gave its nod of approval for Zilxi, Menlo...
Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne Vulgaris
Study FX2016-40 enrolled 447 patients in the United States who were randomized to either FCD105 foam, 3% minocycline foam, 0.3% adapalene foam, or vehicle foam. The Company has begun preparations to conduct an End of Phase 2 meeting with the FDA before the end of this year. FCD105 showed a highly statistically significant improvement compared to vehicle for the endpoints of (1) Investigator’s Global Assessment (IGA) treatment success (IGA score “0” or “1” and at least a two-grade improvement from baseline) and (2) absolute change from baseline in mean inflammatory counts at Week 12.
Menlo Therapeutics Receives FDA Approval of ZILXI™ (minocycline) topical foam, 1.5%, the First Topical Minocycline Treatment for Rosacea
Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that the U.S. Food and Drug Administration (FDA) has approved ZILXI™ (minocycline) topical foam, 1.5%, for the treatment of inflammatory lesions of rosacea in adults. ZILXI, developed as FMX103 by Menlo's wholly-owned subsidiary Foamix Pharmaceuticals Ltd. ("Foamix"), is the first minocycline product of any kind to be approved by the FDA for use in rosacea.